Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on cancer therapies through GSK-3β inhibition, has announced the pricing of its public offering of 2,142,858 shares at $7.00 per share.
The offering, expected to close on September 11, 2025, aims to raise $15.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 321,428 additional shares. Lucid Capital Markets is serving as the sole book-running manager, with Titan Partners Group acting as financial advisor.
The proceeds will be used for working capital and general corporate purposes. The offering is being made pursuant to an effective shelf registration statement on Form S-3.
Positive
- Expected gross proceeds of $15.0 million to strengthen working capital
- Additional potential proceeds through 30-day underwriter option for 321,428 shares
Negative
- Share dilution for existing stockholders through issuance of 2,142,858 new shares
- Offering price of $7.00 may represent a discount to market price
News Market Reaction
On the day this news was published, ACTU declined 19.15%, reflecting a significant negative market reaction. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $42M from the company's valuation, bringing the market cap to $177M at that time.
Data tracked by StockTitan Argus on the day of publication.
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of
Lucid Capital Markets is acting as sole book-running manager for the offering. Titan Partners Group, a division of American Capital Partners, is acting as financial advisor in connection with the offering.
The gross proceeds to the Company from the offering are expected to be approximately
The common stock described above was offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-289988), including a base prospectus, previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. A final prospectus supplement describing the terms of the offering will be filed with the SEC. Copies of the final prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained, when available, from Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Actuate’s expectations on the timing and completion of the offering and the anticipated use of proceeds therefrom. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed under the caption “Risk Factors” in the prospectus supplement related to the offering. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
What is the size and price of Actuate Therapeutics (ACTU) public offering in September 2025?
How will Actuate Therapeutics (ACTU) use the proceeds from its 2025 public offering?
Who are the underwriters for Actuate Therapeutics (ACTU) September 2025 public offering?
When will Actuate Therapeutics (ACTU) 2025 public offering close?
What is the underwriters' option in Actuate Therapeutics (ACTU) public offering?
